Cargando…
Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy – a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol
BACKGROUND: Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The most effective approach to increase long-term survival is CRLM complete resection. Unfortunately, only 10–15% of CRLM are initially considered resectable. The objective response rates (OR...
Autores principales: | Boilève, Alice, Maillard, Aline, Wagner, Mathilde, Dromain, Clarisse, Laurent, Christophe, Dupont Bierre, Eric, Le Sourd, Samuel, Audemar, Franck, Ulusakarya, Ayhan, Guerin-Meyer, Veronique, Smisth, Denis, Pezzella, Veronica, De Baere, Thierry, Goere, Diane, Gelli, Maximiliano, Taieb, Julien, Boige, Valérie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990591/ https://www.ncbi.nlm.nih.gov/pubmed/32000724 http://dx.doi.org/10.1186/s12885-020-6571-7 |
Ejemplares similares
-
Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma—randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol
por: Modesto, Anouchka, et al.
Publicado: (2023) -
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial
por: Aparicio, Thomas, et al.
Publicado: (2020) -
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial – PACHA-01 (NCT02494973)
por: Goéré, Diane, et al.
Publicado: (2018) -
The prodigal son
por: Britten, Benjamin, 1913-1976
Publicado: (1990) -
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results
por: Aparicio, T, et al.
Publicado: (2018)